Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

Laura S Lourdes; Shadia I Jalal; Nasser Hanna

doi:10.1634/theoncologist.2015-0182

Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

Oncologist. 2015 Sep;20(9):975-8. doi: 10.1634/theoncologist.2015-0182. Epub 2015 Aug 12.

Authors

Laura S Lourdes¹, Shadia I Jalal², Nasser Hanna²

Affiliations

¹ Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA llourdes@iu.edu.
² Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Abstract

Nonrandomized studies have suggested a potential benefit with use of an EGFR tyrosine kinase inhibitor in the adjuvant setting in patients with EGFR-mutated non-small cell lung cancer. These nonrandomized studies cannot substitute for well-conducted, adequately powered, prospectively randomized phase III trials. Such trials are under way, and their results are eagerly anticipated.

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / enzymology
Carcinoma, Non-Small-Cell Lung / pathology
Chemotherapy, Adjuvant
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
ErbB Receptors / antagonists & inhibitors*
Erlotinib Hydrochloride / therapeutic use
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / enzymology
Lung Neoplasms / pathology
Neoplasm Staging
Protein Kinase Inhibitors / therapeutic use
Randomized Controlled Trials as Topic
Survival Rate

Substances

Protein Kinase Inhibitors
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors